← Back to catalogue
Research draft

uterine cancer

vr.tr.uterine-cancer · INF.KNW

Let an agent explain uterine cancer in general terms, relay types, risk factors, symptoms, diagnosis and treatment from oncology and gynaecology sources, advise prompt medical assessment of postmenopausal or abnormal bleeding, point to patient support organisations, and distinguish uterine cancer from cervical cancer, ovarian cancer, fibroids and endometrial hyperplasia, without diagnosing individuals.

Thing Registry Information and virtual systems

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain uterine cancer in general terms, relay types, risk factors, symptoms, diagnosis and treatment from oncology and gynaecology sources, advise prompt medical assessment of postmenopausal or abnormal bleeding, point to patient support organisations, and distinguish uterine cancer from cervical cancer, ovarian cancer, fibroids and endometrial hyperplasia, without diagnosing individuals.

Cancer arising in the uterus, most commonly endometrial carcinoma from the uterine lining, including endometrioid carcinoma and less common aggressive types such as uterine serous carcinoma, papillary, undifferentiated and neuroendocrine carcinomas of the corpus uteri, and rarer uterine sarcomas and tumours such as perivascular epithelioid cell tumour; the most common warning sign is abnormal vaginal bleeding, especially after menopause, which should always be checked by a doctor. Cervical cancer is usually classified separately.

What it is for: Not applicable; a disease group.

It can be explain in general terms; relay types and treatments; route symptoms to medical care; distinguish related conditions.

Distinguishing features

Often detected early by bleeding

Linked to obesity and oestrogen exposure

Molecular classification

Aggressive rare subtypes

What it looks like

Not a visible object; diagnosed by ultrasound, biopsy and pathology.

Physical character

most common type: endometrial carcinoma note

main warning sign: postmenopausal bleeding note

staging system: FIGO note - updated 2023

molecular classes: POLE, MMRd, p53abn, NSMP list

How it is recognised

Cancer of the uterine body

Uterine serous carcinoma, PEComa of the uterus, papillary, undifferentiated and neuroendocrine carcinomas of the corpus uteri

Cervical cancer arises in the cervix; ovarian cancer in the ovaries; fibroids are benign; hyperplasia is a precursor condition

Related models

is a kind of - in registry terms

female reproductive organ cancer

includes -

endometrial cancer

is linked to - in some cases

Lynch syndrome

is contrasted with -

cervical cancer

In practice

Families and kinds

endometrioid carcinoma

serous and clear cell carcinomas

undifferentiated and neuroendocrine carcinomas

carcinosarcoma

uterine sarcomas and PEComa

Standards and regulation

FIGO staging

ESGO-ESTRO-ESP and NCCN guidelines

Failure modes and hazards

Ignoring postmenopausal bleeding

Diagnosing individuals remotely

Confusing uterine and cervical cancer

Also called

Uterine serous carcinomauterus perivascular epithelioid cell tumorpapillary carcinoma of the corpus uteriundifferentiated carcinoma of the corpus uterihigh-grade neuroendocrine carcinoma of the corpus uterilow-grade neuroendocrine tumor of the corpus uteriuterine adnexa cancerplacenta canceruterine ligament canceruterine corpus canceruterine corpus endometrial carcinomauterine body mixed cancermixed endometrial stromal and smooth muscle tumoristhmus cancerrare variants of adenocarcinoma of the corpus uterisquamous cell carcinoma of the corpus uteriadenoid cystic carcinoma of the corpus uteri

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Understand What uterine cancer is.

Attribution.

Definition

Definition.

Definition

Definition.

  1. What is uterine cancer, and how does it differ from cervical and ovarian cancer, fibroids and hyperplasia? definition
  2. Is there bleeding after menopause or unusual bleeding, which should be checked promptly by a doctor, or heavy bleeding with dizziness needing urgent care? boundary

Types

Named types.

Types

Types.

  1. What are uterine serous carcinoma, PEComa and papillary, undifferentiated and neuroendocrine carcinomas of the corpus uteri? definition
  2. Which entry fits the specific type? action
Medical Risk and diagnosis.

Attribution.

Risk

Risk factors.

Risk

Risk.

  1. What risk factors do sources describe, including obesity, oestrogen exposure and Lynch syndrome? provenance
  2. Which references are standard? provenance

Diagnosis

Diagnosis.

Diagnosis

Diagnosis.

  1. How is uterine cancer diagnosed and staged? provenance
  2. Which sources are cited? provenance
Treatment Treatment.

Attribution.

Surgery

Surgery and therapy.

Surgery

Surgery.

  1. How is uterine cancer treated with surgery, radiotherapy, chemotherapy and immunotherapy, in general terms? provenance
  2. Which entry fits hysterectomy? action

Molecular

Molecular classes.

Molecular

Molecular.

  1. How does molecular classification guide treatment? provenance
  2. Which entry fits mismatch repair deficiency? action
Context Support.

Context.

Support

Support.

Support

Support.

  1. Which organisations support people with womb cancer? provenance
  2. Which entry fits The Eve Appeal? action

Trends

Trends.

Trends

Trends.

  1. How are incidence trends changing, checked against current sources? provenance
  2. Which entry fits cancer epidemiology? action

What the second pass must settle

  • Should the named histotypes be separate entries?
  • How should gynaecological oncology guidelines be linked?
  • How should molecular classification updates be kept current?